Objective: To evaluate the efficacies of different chemotherapy regimens in different risk sub-groups for the prevention of bladder recurrence after radical nephroureterectomy (RNU). Materials and Methods: Between 2004 and 2012, we recruited 685 patients who underwent RNU for upper tract urothelial carcinoma at 4 Chinese institutions. We assessed whether the type of intravesical chemotherapy regimen affected the bladder recurrence rate in patients with different risk levels after RNU. Results: For all patients, the bladder recurrence rate was lower with intravesical chemotherapy than without, but no significant differences were found between the 2 intravesical chemotherapy regimens (single dose or relatively long-term therapy). We used multivariate analysis to define the risk factors for bladder recurrence and stratified patients into low-, intermediate-, and high-risk sub-groups accordingly. The bladder recurrence rate in the low-risk patients was not significantly different between patients with or without intravesical chemotherapy. However, in the intermediate-risk and high-risk patients, the rate was greater in patients without intravesical chemotherapy than in patients with. Furthermore, the rate was not significantly different between the 2 intravesical chemotherapy regimens in the intermediate-risk patients, while the efficacy of the relatively long-term regimen in high-risk patients remains unclear. Conclusions: Our study showed that an individualized strategy based on patient risk stratification is needed.

Keywords:
Neoplasm recurrence, Urinary bladder, Urinary tract, Intravesical chemotherapy, Urothelium
1.
Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Böhle A, Van Rhijn BW, Kaasinen E, Palou J, Shariat SF: European Association of Urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 2015;68:868-879.
2.
Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG: Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 2009;115:1224-1233.
3.
Yuan H, Mao X, Bai Y, Li H, Liu L, Pu C, Li J, Tang Y, Wei Q, Han P: The effect of intravesical chemotherapy in the prevention of intravesical recurrence after nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis. J Chemother 2015;27:195-200.
4.
Wu WJ, Ke HL, Yang YH, Li CC, Chou YH, Huang CH: Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy? J Urol 2010;183:56-61.
5.
Fang D, Li XS, Xiong GY, Yao L, He ZS, Zhou LQ: Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis. Urol Int 2013;91:291-296.
6.
Hisataki T, Miyao N, Masumori N, Takahashi A, Sasai M, Yanase M, Itoh N, Tsukamoto T: Risk factors for the development of bladder cancer after upper tract urothelial cancer. Urology 2000;55:663-667.
7.
Sakamoto N, Naito S, Kotoh S, Nakashima M, Nakamura M, Ueda T, Kumazawa J: Recurrence of bladder tumors following surgery for transitional cell carcinoma of the upper urinary tract. Eur Urol 1991;20:136-139.
8.
Kang CH, Yu TJ, Hsieh HH, Yang JW, Shu K, Huang CC, Chiang PH, Shiue YL: The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003;98:1620-1626.
9.
Matsui Y, Utsunomiya N, Ichioka K, Ueda N, Yoshimura K, Terai A, Arai Y: Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 2005;65:279-283.
10.
Raman JD, Ng CK, Boorjian SA, Vaughan ED Jr, Sosa RE, Scherr DS: Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology. BJU Int 2005;96:1031-1035.
11.
Zigeuner RE, Hutterer G, Chromecki T, Rehak P, Langner C: Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU Int 2006;98:1181-1186.
12.
Koda S, Mita K, Shigeta M, Usui T: Risk factors for intravesical recurrence following urothelial carcinoma of the upper urinary tract: no relationship to the mode of surgery. Jpn J Clin Oncol 2007;37:296-301.
13.
Novara G, De Marco V, Dalpiaz O, Gottardo F, Bouygues V, Galfano A, Martignoni G, Patard JJ, Artibani W, Ficarra V: Independent predictors of metachronous bladder transitional cell carcinoma (TCC) after nephroureterectomy for TCC of the upper urinary tract. BJU Int 2008;101:1368-1374.
14.
Kobayashi Y, Saika T, Miyaji Y, Saegusa M, Arata R, Akebi N, Takenaka T, Manabe D, Nasu Y, Kumon H: Preoperative positive urine cytology is a risk factor for subsequent development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. World J Urol 2012;30:271-275.
15.
Sauter G, Algaba F, Amin MB, Busch C, Cheville J, Gasser T, Grignon DJ, Hofstädter F, Lopez-Beltran A, Epstein JI: Noninvasive urothelial tumors: WHO classification of non-invasive papillary urothelial tumors; in Eble JN, Sauter G, Epstein JI, Sesterhenn I (eds): World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Lyon, IARC Press, 2004, pp 89-157.
16.
Greene FL, Page DL, Fleming I, Fritz AG, Balch CM, Haller DG, Morrow M (eds): AJCC Cancer Staging Manual, ed 6. New York, Springer-Verlag, 2002.
17.
Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
18.
Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK, Bijnens L: A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council working party on superficial bladder cancer. J Urol 1996;156:1934-1940; discussion 1940-1941.
19.
Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, Kawamura S, Aoki H, Numata I, Takeda A, Namiki S, Namima T, Ikeda Y, Kambe K, Kyan A, Ueno S, Orikasa K, Katoh S, Adachi H, Tokuyama S, et al: Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group trial. J Clin Oncol 2013;31:1422-1427.
20.
O'Brien T, Ray E, Singh R, Coker B, Beard R: Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C trial). Eur Urol 2011;60:703-710.
21.
Sakamoto N, Naito S, Kumazawa J, Ariyoshi A, Osada Y, Omoto T, Fujisawa Y, Morita I, Yamashita H: Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study. Int J Urol 2001;8:212-216.
22.
Li WM, Shen JT, Li CC, Ke HL, Wei YC, Wu WJ, Chou YH, Huang CH: Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol 2010;57:963-969.
23.
Kume H, Teramoto S, Tomita K, Nishimatsu H, Takahashi S, Takeuchi T, Ota N, Kitamura T: Bladder recurrence of upper urinary tract cancer after laparoscopic surgery. J Surg Oncol 2006;93:318-322.
24.
Ou CH, Yang WH: Impact of earlier ureteral ligation on intravesical recurrence during hand-assisted retroperitoneoscopic nephroureterectomy. Urol Int 2014;92:68-73.
25.
Favaretto RL, Shariat SF, Chade DC, Godoy G, Kaag M, Cronin AM, Bochner BH, Coleman J, Dalbagni G: Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? Eur Urol 2010;58:645-651.
26.
Duggan BJ, Gray SB, McKnight JJ, Watson CJ, Johnston SR, Williamson KE: Oligoclonality in bladder cancer: the implication for molecular therapies. J Urol 2004;171:419-425.
27.
Hafner C, Knuechel R, Stoehr R, Hartmann A: Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer 2002;101:1-6.
28.
Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O: Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 1993;342:1087-1088.
29.
Akaza H, Kurth KH, Williams R, Hinotsu S, Jewett MA, Naito K, Okada K, Schellhammer PF, van Velthoven RF, Witjes JA: Intravesical chemotherapy and immunotherapy for superficial tumors basic mechanism of action and future direction. Urol Oncol 1998;4:121-129.
30.
Koga H, Kuroiwa K, Yamaguchi A, Osada Y, Tsuneyoshi M, Naito S: A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J Urol 2004;171:153-157.
31.
Aziz A, Rink M, Gakis G, Kluth LA, Dechet C, Miller F, Otto W, Gierth M, Denzinger S, Schwentner C, Stenzl A, Fisch M, Burger M, Fritsche HM: Preoperative C-reactive protein in the serum: a prognostic biomarker for upper urinary tract urothelial carcinoma treated with radical nephroureterectomy. Urol Int 2014;93:352-360.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.